Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio Inc (NQ: CABA )

15.62 +1.74 (+12.54%)
Streaming Delayed Price Updated: 1:17 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,240,761
Open 14.50
Bid (Size) 15.60 (2)
Ask (Size) 15.66 (4)
Prev. Close 13.88
Today's Range 14.14 - 16.07
52wk Range 3.470 - 19.34
Shares Outstanding 31,355,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Cabaletta Bio
Via Benzinga
Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+66.17%
+66.17%
1 Month
+13.52%
+13.52%
3 Month
+9.23%
+9.23%
6 Month
+54.81%
+54.81%
1 Year
+302.58%
+302.58%

More News

Read More
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Cabaletta Bio
Via GlobeNewswire
Crude Oil Surges 2%; Tharimmune Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Where Cabaletta Bio Stands With Analysts
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
Via Investor Brand Network
Cabaletta Bio: Q3 Earnings Insights
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/24
Via Investor Brand Network
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know
Via Benzinga
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
7 Analysts Have This to Say About Cabaletta Bio
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/23
Via Investor Brand Network
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
From Cellares
Via Business Wire
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
From Cabaletta Bio
Via GlobeNewswire
The Latest Analyst Ratings for Cabaletta Bio
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 9/12
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
Via Benzinga
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.